Home › Melanoma › Florida › Orlando
Studi clinici su Melanoma a Orlando, FL
15 studi su Melanoma cercano partecipanti presso sedi a Orlando e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · a 16 mi di distanza
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
In reclutamentoFase 3
- Orlando Health Cancer Institute, Orlando
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
In reclutamentoFase 2
- Nemours Children's Hospital, Orlando
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
In reclutamentoFase 3
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · a 10 mi di distanza
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
In reclutamentoFase 1
- AdventHealth, Orlando
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
In reclutamentoFase 2
- Orlando Health Cancer Institute, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
In reclutamentoFase 1
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- AdventHealth Orlando, Orlando
- Arnold Palmer Hospital for Children, Orlando
- Nemours Children's Hospital, Orlando
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- AdventHealth Celebration, Celebration · a 17 mi di distanza
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Clermont Oncology Center, Clermont · a 24 mi di distanza
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
In reclutamentoFase 1
- Florida Cancer Specialists - Lake Nona, Orlando
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
In reclutamentoFase 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
In reclutamentoFase 1/2
- Orlando Health Cancer Institute, Orlando
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
In reclutamentoFase 3
- Orlando Health Cancer Institute, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · a 17 mi di distanza
Studi su Melanoma in altre città
- Houston, TX59 studi
- New York City, NY38 studi
- Los Angeles, CA34 studi
- Nashville, TN33 studi
- Pittsburgh, PA31 studi
- Boston, MA26 studi
- Philadelphia, PA23 studi
- San Francisco, CA22 studi
- Durham, NC21 studi
- Atlanta, GA21 studi
- St. Louis, MO21 studi
- Salt Lake City, UT21 studi
Altri studi a Orlando
- Cancro del polmone non a piccole cellule44 studi
- Obesità31 studi
- Cancro metastatico29 studi
- Sovrappeso27 studi
- Morbo di Alzheimer25 studi
- Diabete di tipo 224 studi
- Cancro (tutti i tipi)24 studi
- Cancro al seno23 studi
- Cancro ovarico22 studi
- Colite ulcerosa22 studi
- Cancro ai polmoni21 studi
- Cancro colorettale19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.